Targeted next-generation sequencing of matched localized and metastatic primary high-risk SCCs identifies driver and co-occurring mutations and novel therapeutic targets

Cutaneous squamous cell carcinoma (SCC) is the second most common type of skin cancer with an estimated one million cases per year in the United States, resulting in up to 15,000 deaths annually.1 While only 3-5% of SCCs metastasize, those that do are associated with significant morbidity and mortality due to the lack of standardized and effective treatment options.2 SCC is particularly challenging to manage due to the difficulty in determining which tumors will recur and metastasize and which tumors will be cured with surgery alone.

Source: Journal of Dermatological Science - May 28, 2020 Category: Dermatology Authors: Marissa B. Lobl, Dillon Clarey, Shauna Higgins, Adam Sutton, Laura Hansen, Ashley Wysong Source Type: research